172 related articles for article (PubMed ID: 4570039)
21. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans.
Hossain MA; Maesaki S; Kakeya H; Noda T; Yanagihara K; Sasaki E; Hirakata Y; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 1998 Jul; 42(7):1722-5. PubMed ID: 9661011
[TBL] [Abstract][Full Text] [Related]
22. [Pulmonary cryptococcosis treated by combination therapy of fluconazole plus flucytosine].
Tanaka K; Kohno S; Maesaki S; Mitsutake K; Miyazaki H; Miyazaki T; Tomono K; Kaku M; Koga H; Hara K
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31(12):1528-33. PubMed ID: 8121088
[TBL] [Abstract][Full Text] [Related]
23. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
Klepser ME; Wolfe EJ; Pfaller MA
J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168
[TBL] [Abstract][Full Text] [Related]
24. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and
Rossi SA; de Oliveira HC; Agreda-Mellon D; Lucio J; Mendes-Giannini MJS; García-Cambero JP; Zaragoza O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988099
[TBL] [Abstract][Full Text] [Related]
25. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
27. Synergistic effect of pedalitin and amphotericin B against Cryptococcus neoformans by in vitro and in vivo evaluation.
Sangalli-Leite F; Scorzoni L; Alves de Paula E Silva AC; da Silva JF; de Oliveira HC; de Lacorte Singulani J; Gullo FP; Moraes da Silva R; Regasini LO; Siqueira da Silva DH; da Silva Bolzani V; Fusco-Almeida AM; Soares Mendes-Giannini MJ
Int J Antimicrob Agents; 2016 Nov; 48(5):504-511. PubMed ID: 27742203
[TBL] [Abstract][Full Text] [Related]
28. A flucytosine-resistant Cryptococcus neoformans (serotype D) strain isolated in turkey from cutaneous lesions.
Kantarcioglu AS; Yücel A
Med Mycol; 2002 Oct; 40(5):519-23. PubMed ID: 12462532
[TBL] [Abstract][Full Text] [Related]
29. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous cryptococcosis.
Hernandez AD
Dermatol Clin; 1989 Apr; 7(2):269-74. PubMed ID: 2670372
[TBL] [Abstract][Full Text] [Related]
31. Mycological-diagnostic assessment of the efficacy of amphotericin B + flucytosine to control Cryptococcus neoformans in AIDS patients.
Staib F; Seibold M
Mycoses; 1988 Apr; 31(4):175-86. PubMed ID: 3405247
[No Abstract] [Full Text] [Related]
32. Treatment of murine cryptococcosis with minocycline and amphotericin B.
Graybill JR; Mitchell L
Sabouraudia; 1980 Jun; 18(2):137-44. PubMed ID: 6999643
[TBL] [Abstract][Full Text] [Related]
33. Therapy of experimental meningeal and disseminated cryptococcosis.
Van Cutsem J
Mycoses; 1993; 36(11-12):357-67. PubMed ID: 7935566
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis.
Lu R; Hollingsworth C; Qiu J; Wang A; Hughes E; Xin X; Konrath KM; Elsegeiny W; Park YD; Atakulu L; Craft JC; Tramont EC; Mannino R; Williamson PR
mBio; 2019 May; 10(3):. PubMed ID: 31138748
[No Abstract] [Full Text] [Related]
35. Immunomodulator tuftsin increases the susceptibility of Cryptococcus neoformans to liposomal amphotericin B in immunocompetent BALB/c mice.
Khan MA; Owais M
J Drug Target; 2005 Aug; 13(7):423-9. PubMed ID: 16308211
[TBL] [Abstract][Full Text] [Related]
36. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.
Friese G; Discher T; Füssle R; Schmalreck A; Lohmeyer J
AIDS; 2001 Nov; 15(17):2344-5. PubMed ID: 11698718
[No Abstract] [Full Text] [Related]
37. Cryptococcal meningitis treated with 5-fluorocytosine and amphotericin B.
Stewart JD
East Afr Med J; 1977 Dec; 54(12):684-5. PubMed ID: 612428
[No Abstract] [Full Text] [Related]
38. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.
Rodero L; Córdoba S; Cahn P; Hochenfellner F; Davel G; Canteros C; Kaufman S; Guelfand L
J Antimicrob Chemother; 2000 Feb; 45(2):239-42. PubMed ID: 10660509
[TBL] [Abstract][Full Text] [Related]
39. Interaction of chemotherapy and immune defenses in experimental murine cryptococcosis.
Graybill JR; Craven PC; Mitchell LF; Drutz DJ
Antimicrob Agents Chemother; 1978 Nov; 14(5):659-67. PubMed ID: 365086
[TBL] [Abstract][Full Text] [Related]
40. [Cryptococcosis of the central nervous system: evaluation of amphotericin-B, 5-fluorocytosine and miconazole therapy in 18 cases].
Nobrega JP; Livramento JA; Machado LR; Spina-França A
Arq Neuropsiquiatr; 1979 Mar; 37(1):28-33. PubMed ID: 380531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
